Viveka Frykman

Viveka Frykman

Auto-generated profile, based on publicly available information

Viveka Frykman

Department of Clinical Sciences, Danderyd University Hospital, Karolinska Institutet, Stockholm, Sweden (V.F.).

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 May 2011 in European Heart Journal
Verified
Journal Article
Open access
PDF file
MWMattias Wieloch
Mattias Wieloch
ASAnders Själander
Anders Själander
VFViveka Frykman
Viveka Frykman
MRMårten Rosenqvist
Mårten Rosenqvist
NENiclas Eriksson
Niclas Eriksson
PSPeter J. Svensson
Peter J. Svensson
In anticoagulation treatment with warfarin, the risk of thrombo-embolic events must be weighed against the risk of bleeding. Time in therapeutic range (TTR) is an important tool to assess the quality of anticoagulation treatment, and has been shown to correlate with less bleeding and thrombo-embolic complications. AuriculA, the Swedish national quality registry for atrial fibrillation and anticoagulation, is used for follow-up and dosage control of warfarin. This is the first report of TTR in AuriculA and, in a subgroup of two centres, bleeding and thrombo-embolic complications during 2008. Prothrombin complex (International normalized ratio) values from 18 391 patients in 67 different centres were analysed. The mean (SD) age was 70 (12) years. The main indications for warfarin treatment were: atrial fibrillation (64%), venous thromboembolism (19%), and heart valve dysfunction (13%). Time in therapeutic range for all patients was 76.2%. The mean weekly dose of warfarin decreased with age and TTR increased with age. In 4273 patients from two centres in AuriculA, the frequency of major bleedings and venous/arterial thrombo-embolism were 2.6 and 1.7% and for atrial fibrillation, 2.6 and 1.4%, per treatment year, respectively. A correlation between age and the risk of major bleeding (P< 0.001), but not thrombo-embolic complications (P= 0.147), was seen. Compared with prospective randomized trials of warfarin treatment, TTR in the AuriculA population was higher. Complications were low, probably due to the organization of anticoagulation treatment in Sweden. Use of the AuriculA dosing programme could have contributed to the results by keeping dosing regimens consistent over all centres.

19 November 2010 in EP Europace
Verified
Journal Article
Open access
PDF file
NENils Edvardsson
Nils Edvardsson
DVDespina Voulgaraki
Despina Voulgaraki
CGClaudio Garutti
Claudio Garutti
PSPelle Stolt
Pelle Stolt
NLNicholas J. Linker
Nicholas J. Linker
JVJ. Vlašίnová
J. Vlašίnová
To collect information on the use of the Reveal implantable loop recorder (ILR) in the patient care pathway and to investigate its effectiveness in the diagnosis of unexplained recurrent syncope in everyday clinical practice. Prospective, multicentre, observational study conducted in 2006–2009 in 10 European countries and Israel. Eligible patients had recurrent unexplained syncope or pre-syncope. Subjects received a Reveal Plus, DX or XT. Follow up was until the first recurrence of a syncopal event leading to a diagnosis or for ≥1 year. In the course of the study, patients were evaluated by an average of three different specialists for management of their syncope and underwent a median of 13 tests (range 9–20). Significant physical trauma had been experienced in association with a syncopal episode by 36% of patients. Average follow-up time after ILR implant was 10 ± 6 months. Follow-up visit data were available for 570 subjects. The percentages of patients with recurrence of syncope were 19, 26, and 36% after 3, 6, and 12 months, respectively. Of 218 events within the study, ILR-guided diagnosis was obtained in 170 cases (78%), of which 128 (75%) were cardiac. A large number of diagnostic tests were undertaken in patients with unexplained syncope without providing conclusive data. In contrast, the ILR revealed or contributed to establishing the mechanism of syncope in the vast majority of patients. The findings support the recommendation in current guidelines that an ILR should be implanted early rather than late in the evaluation of unexplained syncope.

1 March 2001 in Clinical Cardiology
Verified
Journal Article
Open access
PDF file
MFMats Frick
Mats Frick
VFViveka Frykman
Viveka Frykman
MJMats Jensen‐Urstad
Mats Jensen‐Urstad
JÖJan Östergren
Jan Östergren
Background: The recurrence rate of atrial fibrillation (AF) after elective cardioversion is high.Hypothesis: The study aimed to identify clinical predictors for successful electrical cardioversion and maintenance of sinus rhythm after a first electrical cardioversion in patients with persistent AF without concomitant antiarrhythmic drugs of class I and III.Methods: Consecutive outpatients (n = 166) with persistent AF for > 1 month, scheduled for elective cardioversion, were prospectively included in the study. A clinical investigation, echocardiographic assay, and Holter electrocardiogram (ECG) before and ECG 4 weeks after cardioversion, were performed in all patients.Results: The mean age of the patients was 68 years (range 45–83) and duration of AF was 5 (1–48) months. Sinus rhythm was established in 124 (75%) patients. In multivariate analysis, only duration of AF < 6 months (p < 0.04, odds ratio [OR] 2.2, 95% confidence interval [CI] 1.1 to 4.7) and patients weight (p < 0.03, OR 2.3, 95% CI 1.1 to 4.8 for weight < 80 kg) were identified as independent predictors of successful cardioversion. At 4 weeks after cardioversion, only 46 (37%) of 124 patients maintained sinus rhythm. Independent factors for maintenance of sinus rhythm, in multivariate analysis, were AF < 3 months (p < 0.04, OR 2.5, 95% CI 1.1 to 5.6), treatment with beta blockers (p < 0.00001, OR 7.0, 95% CI 3.0 to 16.3) or verapamil/diltiazem (p < 0.04, OR 3.6, 95% CI 1.0 to 12.1), and right atrial dimension < 37 mm (p < 0.02, OR 5.9, 95% CI 1.4 to 25.4).Conclusions: In patients with persistent AF, the patient's weight and the duration of AF are independent predictors for a successful cardioversion. Short duration of AF, treatment with beta blockers or verapamil/diltiazem, and right atrial area/dimension are independent predictors for maintenance of sinus rhythm.

28 January 2014 in Circulation
Verified
Journal Article
Closed access
PDF file
AWAnnika Kinch Westerdahl
Annika Kinch Westerdahl
JSJohanna Sjöblom
Johanna Sjöblom
AMAnne-Cathrine Mattiasson
Anne-Cathrine Mattiasson
MRMårten Rosenqvist
Mårten Rosenqvist
VFViveka Frykman
Viveka Frykman
Background—: Several trials have demonstrated improved survival with implantable cardioverter-defibrillator (ICD) therapy. The cause and nature of death in the ICD population have been insufficiently investigated. The objective of this study was to analyze ICDs from deceased patients to assess the incidence of ventricular tachyarrhythmias, the occurrence of shocks, and possible device malfunction. Methods and Results—: We prospectively analyzed intracardiac electrograms in 125 explanted ICDs. The incidence of ventricular tachyarrhythmia, including ventricular fibrillation, and shock treatment was assessed. Ventricular tachyarrhythmia occurred in 35% of the patients in the last hour of their lives; 24% had an arrhythmic storm, and 31% received shock treatment during the last 24 hours. Arrhythmic death was the primary cause of death in 13% of the patients, and the most common cause of death was congestive heart failure (37%). More than half of the patients (52%) had a do-not-resuscitate order, and 65% of them still had the ICD shock therapies activated 24 hours before death. Possible malfunctions of the ICD were found in 3% of all patients. Conclusions—: More than one third of the patients had a ventricular tachyarrhythmia within the last hour of life. Cardiac death was the primary cause and heart failure the specific cause of death in the majority of the cases. Devices remained active in more than half of the patients with a do-not-resuscitate order; almost one fourth of these patients received at least 1 shock in the last 24 hours of life.

1 January 2009 in Scandinavian Cardiovascular Journal
Verified
Journal Article
Closed access
PDPeter Sobocinski Doliwa
Peter Sobocinski Doliwa
VFViveka Frykman
Viveka Frykman
MRMårten Rosenqvist
Mårten Rosenqvist
We evaluated a short-term ECG, thumb ECG, for detection of asymptomatic atrial fibrillation (AF) episodes. The aim was to evaluate registration efficacy, sensitivity, specificity, quality and feasibility in patients with special emphasis on asymptomatic AF. One hundred patients registered their cardiac rhythm with 12-lead ECG immediately followed by thumb ECG. The registrations were compared blindly. A second group of 12 patients, who had successfully undergone cardioversion, performed rhythm registration twice daily for 30 days. A third group of 606 individuals underwent an AF screening procedure. Thumb ECG correctly diagnosed AF (sensitivity) in 96% and sinus rhythm (specificity) in 92% compared with 12-lead ECG. In the group of cardioverted patients, 466 registrations were validated: 95% had satisfactory quality for diagnosis: four patients experienced AF recurrence in which three were asymptomatic. In the third group 12 persons were diagnosed with AF, six of these had neither symptoms nor a history of AF. Short-term ECG is able to diagnose AF with a high sensitivity, specificity and simple application making detection of asymptomatic AF possible for screening purposes.

11 July 2012 in EP Europace
Verified
Journal Article
Open access
PDF file
LFLeif Friberg
Leif Friberg
JEJohan Engdahl Engdahl
Johan Engdahl Engdahl
VFViveka Frykman
Viveka Frykman
ESEmma Svennberg
Emma Svennberg
LLLars-Åke Levin
Lars-Åke Levin
MRMårten Rosenqvist
Mårten Rosenqvist
Atrial fibrillation (AF) is important because it is common and is a major cause of stroke unless treated with oral anticoagulant. The prevalence of AF increases with age as does the risk of stroke. At 75 years the risk from age alone is so high that current guidelines recommend anticoagulation even in the absence of other risk factors. Atrial fibrillation is often asymptomatic and only discovered by chance or when a stroke already has occurred. We have launched a major screening study for silent AF in which 25 000 Swedes aged 75 and 76 years are randomized to either participate in a screening programme using ambulant intermittent electrocardiogram (ECG) recording to detect silent AF, or act as a control group. Patients in whom AF is detected are offered cardiological examination and anticoagulant treatment according to current guidelines. The cohort and the controls will be followed prospectively for 5 years after the inclusion of the first participant. An interim analysis will be made after 3 years. Our hypothesis is that screening for AF will reduce stroke incidence in the screened population, and that this screening will prove to be cost effective. Secondary endpoints are: any thromboembolic event, intracranial bleeding, other major bleeding, first ever diagnosis of dementia, death from any cause, and a composite of these endpoints.